Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.
Curr Opin Ophthalmol. 2021 May 1;32(3):191-197. doi: 10.1097/ICU.0000000000000757.
Antivascular endothelial growth factor (VEGF) agents have provided historic therapeutic breakthroughs in the treatment of retinal disease. New anti-VEGF agents are emerging for the treatment of retinal vascular diseases. Both systemic and ocular adverse effect need to be understood in managing patients. This review aims to highlight the adverse effects seen with routine use of bevacizumab, ranibizumab and aflibercept, as well as with new medications such as brolucizumab and abicipar.
We review the recent findings of intraocular inflammation (IOI) of brolucizumab and abicipar in the context of the efficacy and safety reported with the routine anti-VEGF agents. Specifically, brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of IOI, which has not been seen in other anti-VEGF medications. In addition, abicipar appears to cause IOI at a higher rate of patients than other anti-VEGF agents have previously.
Newer anti-VEGF agents pose a significant risk of adverse events not seen with routine anti-VEGF agents.
抗血管内皮生长因子（VEGF）药物在治疗视网膜疾病方面取得了历史性的治疗突破。新的抗 VEGF 药物正被用于治疗视网膜血管疾病。在治疗患者时，需要了解全身和眼部的不良反应。本综述旨在强调在常规使用贝伐单抗、雷珠单抗和阿柏西普时以及在使用新药物如布罗利珠单抗和阿柏西普时所观察到的不良反应。
我们在报告的常规抗 VEGF 药物的疗效和安全性的背景下，综述了 brolucizumab 和 abicipar 的眼内炎症（IOI）的最新发现。具体来说，brolucizumab 已被报道在 IOI 情况下引起闭塞性视网膜血管炎，而其他抗 VEGF 药物则没有这种情况。此外，与其他抗 VEGF 药物相比，阿柏西普似乎在更高比例的患者中引起 IOI。
新型抗 VEGF 药物带来了与常规抗 VEGF 药物不同的严重不良反应风险。
